8MM respiratory syncytial virus prophylaxis market to hit $6.2b by 2030

Thanks to the introduction of new monoclonal antibodies and vaccines.

The respiratory syncytial virus (RSV) prophylaxis market across eight major markets (8MM) is projected to reach $6.2b by 2030 at a compound annual growth rate of 26.7%, said GlobalData.

The sector’s expansion is attributed to the introduction of new monoclonal antibodies (mAbs) and vaccines targeting maternal, adult, and paediatric RSV cases.

Six additional products currently in late-stage development are anticipated to launch by 2030.

“In 2020 the only product marketed for RSV prophylaxis was AstraZeneca/AbbVie’s Synagis (palivizumab), a mAb only used in high-risk infants,” the report said.

Meanwhile, Synagis is likely to be replaced by Beyfortus and clesrovimab for preventing RSV infections in infants, said Anaelle Tannen, Infectious Disease Analyst at GlobalData.

Key opinion leaders highlighted several limitations of Synagis, including its short half-life requiring monthly doses and high cost, which restrict its clinical use despite its efficacy in high-risk infants.

“While some unmet needs will still remain, there will be vast improvement in the RSV prophylaxis space over the forecast period, owing to the influx of innovative new products,” Tannen said.